HRPC(SH:600829) Xin Lang Cai Jing·2025-11-04 02:10Core Viewpoint - The stock of Renmin Tongtai has experienced fluctuations, with a recent decline of 2.00%, while showing an overall increase of 17.47% year-to-date, indicating mixed investor sentiment and market performance [1][2]. Company Overview - Renmin Tongtai Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on February 19, 1994, and listed on February 24, 1994. The company primarily engages in pharmaceutical wholesale, retail, and medical services, selling a variety of products including traditional and Western medicines, medical devices, and health products [2]. - The revenue composition of Renmin Tongtai includes 57.72% from wholesale to medical clients, 22.26% from wholesale to commercial clients, 18.91% from retail, and minor contributions from other sources [2]. Financial Performance - For the period from January to September 2025, Renmin Tongtai reported a revenue of 7.846 billion yuan, reflecting a year-on-year growth of 2.19%. However, the net profit attributable to shareholders decreased by 45.69% to 112 million yuan [2]. - The company has distributed a total of 1.671 billion yuan in dividends since its A-share listing, with 83.504 million yuan distributed over the past three years [3]. Market Activity - As of November 4, Renmin Tongtai's stock price was 8.81 yuan per share, with a market capitalization of 5.109 billion yuan. The stock has seen a trading volume of 53.6751 million yuan and a turnover rate of 1.05% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on July 21, where it recorded a net purchase of 9.0087 million yuan [1].